Immunomedics (IMMU +1.3%) bucks the broad market selloff, albeit on below-average volume, with its resubmission of a U.S. marketing application seeking accelerated approval to use antibody-drug conjugate sacituzumab govitecan to treat patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior lines of therapy.
The company received a CRL in January in response to its initial filing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.